Regulatory Filings • Dec 4, 2025
Regulatory Filings
Open in ViewerOpens in native device viewer
Bulletin from the extraordinary general meeting of Inify Laboratories AB
Today, December 4, 2025, an extraordinary general meeting was held in INIFY
Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting,
66,655,976 shares were represented, corresponding to 84.5 per cent of the total
number of shares and votes in the Company. Below follows a summary of the
resolution adopted at the meeting.
Resolution on directed share issues
The general meeting resolved, in accordance with the board of directors'
proposal, on a directed issue of shares to SB1 Markets AS for onward transfer to
major shareholders in the Company (the "Private Placement") and on a directed
issue of shares to SB1 Markets AS for onward transfer to other shareholders in
the Company (the "Repair Issue"). Details and timetable for the Private
Placement and the Repair Issue are set out in the Company's press releases dated
November 12, 2025 and December 3, 2025, respectively.
For further information, contact:
Ann-Charlotte Linderoth, CFO
E-mail: [email protected]
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)
Have a question? We'll get back to you promptly.